European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact
Guidelines

Upper Urinary Tract Urothelial Cell Carcinoma

Want to read the guideline in your own time? Download the PDF

Download full guideline

Looking for a quick overview? Check the pocket guidelines.

Download pocket guidelines
Full text guidelineSummary of ChangesPublications & AppendicesPanelRelated content
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
2021
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • No elements found. Consider changing the search query.
  • List is empty.

The literature for the complete document has been assessed and updated, whenever relevant. Conclusions and recommendations have been rephrased and added to throughout the current document.

Key changes for the 2021 print:

  • Chapter 5 – Diagnosis, new section 5.3 – 18F-Fluorodeoxglucose positron emission tomography/computed tomography (FDT-PET/CT) was added resulting in a change of a recommendation.

5.7 Summary of evidence and guidelines for the diagnosis of UTUC

RecommendationStrength rating
Magnetic resonance urography or FDG-PET/CT may be used when CT is contraindicated.Weak

 

  • Chapter 6 – Prognosis, additional information has been addeded and this section was restructured, resulting in changes to Figures 6.1 and 6.2 and the Summary of evidence. New sections 6.2.2 – Perioperative predictive tools for high risk disease and 6.3 – Bladder recurrence were added.

6.4 Summary of evidence and guidelines for the prognosis of UTUC

Summary of evidenceLE
Models are available to predict non-organ confined disease and altered prognosis after RNU.3
Patient, tumour and treatment-related factors impact risk of bladder recurrence.3

 

  • Chapter 7 – Treatment, Sections 7.1.2 – Management of high-risk non-metastatic UTUC and 7.1.3.3 – Induction chemotherapy were added. Section 7.1.5 – Post-operative bladder instillation was expanded, resulting in a changed recommendation.

7.1.6 Summary of evidence and guidelines for the management of high-risk non-metastatic UTUC 

Summary of evidenceLE
Post-operative chemotherapy improves disease-free survival.1b

 

RecommendationStrength rating
Offer post-operative systemic platinum-based chemotherapy to patients with muscle-invasive UTUC.Strong

 

  • Section 7.2 – Metastatic disease, systemic treatments, considerable new data has been added in both the first-line and second-line setting, not resulting in a change to the recommendations. A change was made to Figure 7.2 – Surgical treatment according to location and status, to include post-operative chemotherapy as an option for high-risk tumours.

 

About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer